Asieris Pharmaceuticals (stock code: 688176.SH), a China-based global biopharma company, announced on Wednesday that it has named Dr Badrinath Konety as an advisor to the company's Scientific Advisory Board.
Dr Konety has over 30 years of clinical research and medical practice experience in the field of genitourinary oncology. Presently, he is the president of Allina Health Cancer Institute and chief system research officer and also a professor in the Department of Urology, Rush Medical College. He has held the position of professor and dougherty family chair in Uro-Oncology, and chairman, Department of Urology, University of Minnesota. He has served as CEO for University of Minnesota Physicians and Dean of Rush Medical College. He has held various leading positions and offices in professional organisations such as the presidents of Society of Academic Urologists and Societe Internationale d'Urologie.
Dr Kevin Pan, Asieris founder and CEO, said, 'We are honoured to have Dr Konety in our Scientific Advisory Board. With his profound expertise in the global genitourinary filed, we are confident that Dr. Konety will play a critical role in helping Asieris define and optimise growth objectives and strategies to accelerate its innovation ambitions to become a global specialty biopharmaceutical company.'
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
AbbVie announces interim evaluation of Atogepant Phase three, open-label 156-week extension study
Precision Epigenomics partners with TruDiagnostic
Modalis partners with Ginkgo Bioworks
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
Algiax Pharmaceuticals reveals update on chronic neuropathic pain study